A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy Volunteer
Interventions
DRUG

Midazolam, IV

2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).

DRUG

Midazolam, oral

0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.

DRUG

RO5186582

RO5186582 120 mg film-coated release tablet.

Trial Locations (1)

LS2 9LH

Leeds

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02254759 - A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants | Biotech Hunter | Biotech Hunter